Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Intellia Therapeutics Stock a Buy?

TheMotleyFool

0 0

A relatively new technology called CRISPR/Cas9, or CRISPR for short, has the potential to change the way doctors treat genetic diseases, and may even lead to cures. That would be wonderful news for patients, but as with any new technology, the road from idea to reality can be long and fraught with missteps and good luck.

CRISPR Therapeutics (NASDAQ: CRSP), Editas Medicine (NASDAQ: EDIT), and Intellia Therapeutics (NASDAQ: NTLA) make up a cadre of public biotech companies investors can choose from to gain exposure to the burgeoning CRISPR field.

Image Source: Getty Images.

Source Fool.com

Like: 0

NTLA

Share